연구성과로 돌아가기
2022 연구성과 (75 / 280)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations | A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for tegoprazan and its major metabolite M1 was developed to predict PK and PD profiles under various scenarios. The PBPK model for tegoprazan and M1 was developed and predicted using the SimCYP((R)) simulator and verified using clinical study data obtained after a single administration of tegoprazan. The established PBPK/PD model was used to predict PK profiles after repeated administrations of tegoprazan, postprandial PK profiles, and intragastric pH changes. The predicted tegoprazan and M1 concentration-time profiles fit the observed profiles well. The arithmetic mean ratios (95% confidence intervals) of the predicted to observed values for the area under the curve (AUC(0-24 h)), maximum plasma drug concentration (C-max), and clearance (CL) for tegoprazan and M1 were within a 30% interval. Delayed time of maximum concentration (T-max) and decreased C-max were predicted in the postprandial PK profiles compared with the fasted state. This PBPK/PD model may be used to predict PK profiles after repeated tegoprazan administrations and to predict differences in physiological factors in the gastrointestinal tract or changes in gastric acid pH after tegoprazan administration. | Jeong, Hyeon-Cheol; Kim, Min-Gul; Wei, Zhuodu; Lee, Kyeong-Ryoon; Lee, Jaehyeok; Song, Im-Sook; Shin, Kwang-Hee | Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Jeonbuk Natl Univ, Med Sch, Dept Pharmacol, Jeonju 54907, South Korea; Korea Res Inst Biosci & Biotechnol, Lab Anim Resource Ctr, Cheongju 28116, South Korea; Univ Sci & Technol, Dept Biosci, Daejeon 34113, South Korea | 57196346934; 38260938400; 57764624700; 35409534300; 57219980183; 7201564500; 35216279300 | houkiboshi01@knu.ac.kr;mgkim@jbcp.kr;2021221434@knu.ac.kr;kyeongrlee@kribb.re.kr;here0723@gmail.com;isssong@knu.ac.kr;kshin@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 6 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.07 | 2025-06-25 | 7 | 10 | tegoprazan; PBPK; pharmacodynamics; gastric pH; food effect | PROTON PUMP INHIBITORS; CYP2C19 GENETIC POLYMORPHISMS; GASTROESOPHAGEAL-REFLUX; FORMULATION; STRATEGY; ULCERS; DRUGS | food effect; gastric pH; PBPK; pharmacodynamics; tegoprazan | tegoprazan; area under the curve; Article; controlled study; drug blood level; drug clearance; drug elimination; human; human cell; in vitro study; incubation time; liquid chromatography-mass spectrometry; liver microsome; open study; prediction; single drug dose; stomach pH; trend study; ultra performance liquid chromatography | English | 2022 | 2022-06 | 10.3390/pharmaceutics14061298 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling | Matrix metalloproteinase 11 (MMP11), a member of the MMP family involved in the degradation of the extracellular matrix, has been implicated in cancer progression. Despite the stromal expression of MMP11 in breast cancer, the prognostic significance and role of MMP11 in immune or stromal cells of breast cancer remain unclear. Based on the immunohistochemical analysis of breast cancer tissues from 497 patients, we demonstrated that MMP11 expression in mononuclear inflammatory cells (predominantly macrophages) is an independent negative prognostic factor in breast cancer, whereas MMP11 expression in tumor cells and fibroblasts is not associated with patient survival. Enforced MMP11 expression in breast cancer cells did not promote cell proliferation and migration. However, MMP11-overexpressing macrophages enhanced the migration of HER2-positive (HER2+) breast cancer cells, recruitment of monocytes, and tube formation of endothelial cells. Furthermore, we found that the chemokine CCL2 secreted from MMP11-overexpressing macrophages activated the MAPK pathway via its receptor CCR2 in breast cancer cells, thereby promoting the migration of HER2+ breast cancer cells through MMP9 upregulation. We also found that MMP11 expression in macrophages was stimulated by MMP11-overepressing HER2+ breast cancer cells. Collectively, our findings provide evidence that MMP11 in macrophages may play a pro-tumoral role in HER2+ breast cancer through interaction with cancer cells, monocytes, and endothelial cells. The authors demonstrate that matrix metalloproteinase 11 (MMP11) expression in mononuclear inflammatory cells (predominantly macrophages) is an independent negative prognostic factor in breast cancer, whereas tumoral MMP11 expression is not associated with patient survival. This study also shows that MMP11-overexpressing macrophages promote the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling, suggesting a pro-tumoral role of MMP11 in macrophages in HER2-positive breast cancer through interaction with cancer cells and other cells in the tumor microenvironment. | Kang, Shin Ung; Cho, Soo Youn; Jeong, Hyojin; Han, Jinil; Chae, Ha Yeong; Yang, Hobin; Sung, Chang Ohk; Choi, Yoon-La; Shin, Young Kee; Kwon, Mi Jeong | Kyungpook Natl Univ, Coll Pharm, Vessel Organ Interact Res Ctr, Daegu, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea; Gencurix Inc, Seoul, South Korea; Seoul Natl Univ, Coll Pharm, Lab Mol Pathol & Canc Genom, Seoul, South Korea; Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Lab Canc Genom & Mol Pathol, Samsung Biomed Res Inst,Samsung Med Ctr, Seoul, South Korea; Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea; Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea | Shin, Young/C-8929-2011; Kim, Jee/J-5441-2012 | 57345619700; 7404885257; 57226758743; 56982070700; 57344707400; 57207201317; 8607304000; 7404777529; 26428533000; 35278164800 | mjkwon94@knu.ac.kr; | LABORATORY INVESTIGATION | LAB INVEST | 0023-6837 | 1530-0307 | 102 | 4 | SCIE | MEDICINE, RESEARCH & EXPERIMENTAL;PATHOLOGY | 2022 | 5 | 17.8 | 6.86 | 2025-06-25 | 45 | 44 | TUMOR-ASSOCIATED MACROPHAGES; CHEMOATTRACTANT PROTEIN-1; STROMAL CELLS; CCL2; MICROENVIRONMENT; ACTIVATION; EXPRESSION; SURVIVAL | Breast Neoplasms; Chemokine CCL2; Endothelial Cells; Female; Humans; Macrophages; Matrix Metalloproteinase 11; Monocytes; Receptors, CCR2; antineoplastic agent; chemokine receptor CCR2; gelatinase B; monocyte chemotactic protein 1; stromelysin 3; CCL2 protein, human; CCR2 protein, human; chemokine receptor CCR2; MMP11 protein, human; monocyte chemotactic protein 1; stromelysin 3; adult; Article; BT-474 cell line; cancer chemotherapy; cancer prognosis; cancer radiotherapy; cancer staging; cancer surgery; cancer survival; cell migration; cell proliferation; controlled study; disease free survival; endothelium cell; female; flow cytometry; gene expression; human; human epidermal growth factor receptor 2 positive breast cancer; human tissue; immunohistochemistry; immunoreactivity; in vitro study; macrophage; major clinical study; MAPK signaling; MCF-7 cell line; MDA-MB-231 cell line; middle aged; monocyte; overall survival; protein expression; real time reverse transcription polymerase chain reaction; SK-BR-3 cell line; tissue microarray; treatment outcome; tubulogenesis; tumor volume; tumor-associated macrophage; upregulation; Western blotting; breast tumor; macrophage; metabolism; monocyte; pathology | English | 2022 | 2022-04 | 10.1038/s41374-021-00699-y | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Mono and Multiple Tumor-Targeting Ligand-Coated Ultrasmall Gadolinium Oxide Nanoparticles: Enhanced Tumor Imaging and Blood Circulation | Hydrophilic and biocompatible PAA-coated ultrasmall Gd2O3 nanoparticles (d(avg) = 1.7 nm) were synthesized and conjugated with tumor-targeting ligands, i.e., cyclic arginylglycylaspartic acid (cRGD) and/or folic acid (FA). FA-PAA-Gd2O3 and cRGD/FA-PAA-Gd2O3 nanoparticles were successfully applied in U87MG tumor-bearing mice for tumor imaging using T-1 magnetic resonance imaging (MRI). cRGD/FA-PAA-Gd2O3 nanoparticles with multiple tumor-targeting ligands exhibited higher contrasts at the tumor site than FA-PAA-Gd2O3 nanoparticles with mono tumor-targeting ligands. In addition, the cRGD/FA-PAA-Gd2O3 nanoparticles exhibited higher contrasts in all organs, especially the aorta, compared with those of the FA-PAA-Gd2O3 nanoparticles, because of the blood cell hitchhiking effect of cRGD in the cRGD/FA-PAA-Gd2O3 nanoparticles, which prolonged their circulation in the blood. | Ho, Son Long; Yue, Huan; Lee, Sangyeol; Tegafaw, Tirusew; Ahmad, Mohammad Yaseen; Liu, Shuwen; Al Saidi, Abdullah Khamis Ali; Zhao, Dejun; Liu, Ying; Nam, Sung-Wook; Chae, Kwon Seok; Chang, Yongmin; Lee, Gang Ho | Kyungpook Natl Univ, Coll Nat Sci, Dept Chem, Taegu 41566, South Korea; Kyungpook Natl Univ, Dept Med & Biol Engn, Taegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, Dept Mol Med, Taegu 41944, South Korea; Kyungpook Natl Univ, Teachers Coll, Dept Biol Educ, Taegu 41566, South Korea | ; Ho, Son Long/P-3183-2015; Ahmad, Mohammad/AAH-2164-2020; Nam, Sung-Wook/V-5519-2019 | 55659242700; 57200329016; 57875786900; 55983618600; 57203054570; 57208926248; 57217492867; 57222567792; 57221731093; 16167127700; 15743626400; 7501840633; 7404851841 | sonlongh@gmail.com;yuehuan888@gmail.com;tkdduf1405@knu.ac.kr;tirukorea@gmail.com;yaseen.knu@gmail.com;liushuwen0701@gmail.com;abdullah_al_saidi@hotmail.com;djzhao.chem@gmail.com;ly1124161@gmail.com;nams@knu.ac.kr;kschae@knu.ac.kr;ychang@knu.ac.kr;ghlee@mail.knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 7 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.75 | 2025-06-25 | 5 | 7 | ultrasmall Gd2O3 nanoparticle; folic acid; cRGD; multiple tumor-targeting ligand; tumor imaging; blood circulation enhancement | MRI CONTRAST AGENTS; FOLATE RECEPTOR; NEUTRON-CAPTURE; RAPID SYNTHESIS; DUAL-LIGAND; PHARMACOKINETICS; OPSONIZATION; DOXORUBICIN; CLEARANCE; COMPLEXES | blood circulation enhancement; cRGD; folic acid; multiple tumor-targeting ligand; tumor imaging; ultrasmall Gd<sub>2</sub>O<sub>3</sub> nanoparticle | arginylglycylaspartic acid; folic acid; ligand; metal oxide nanoparticle; polyacrylic acid; ultrasmall gadolinium oxide nanoparticle; unclassified drug; animal cell; animal experiment; animal model; aorta; Article; cell viability; circulation; coating (procedure); contrast; controlled study; crystal structure; cytotoxicity assay; human; human cell; hydrophilicity; image enhancement; in vitro study; male; mouse; multiple tumor; nonhuman; nuclear magnetic resonance imaging; one pot synthesis; physical chemistry; relaxation time | English | 2022 | 2022-07 | 10.3390/pharmaceutics14071458 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | New Autonomous Water-Enabled Self-Healing Coating Material with Antibacterial-Agent-Releasing Properties | A new autonomous water-enabled self-healing coating with antibacterial-agent-releasing capability was developed for the first time by precipitating an aqueous solution of hydrogen-bonded tannic acid (TA) and polyethylene glycol (PEG) (TA: 5 mg/mL; PEG: 5 mg/mL with M-W = 100 kDa) to form a smooth, uniform coating layer with an average roughness of 0.688 nm and thickness of 22.3 mu m on a polymethyl methacrylate (PMMA) substrate after 10 min of incubation. Our method is cost- and time-efficient, as the hydrophilic coating (water contact angle = 65.1 degrees) forms rapidly, binding strongly to the PMMA substrate (adhesive energy = 83 mJ/m(2)), without the need for pretreatment or surface modification, and is capable of rapid self-repair (approximately 5 min) through hydrogen bonding in aqueous media. Furthermore, adding 0.5 mg/mL of chlorhexidine acetate (CHX), a commonly used antibacterial agent in dentistry, into the TA-PEG emulsion allowed the release of 2.89 mu g/mL of the drug from the coating layer, which is promising for actively inhibiting the vitality and growth of bacteria around PMMA dental restorations. The use of CHX-loaded TA-PEG hydrogen-bonded complexes is highly favorable for the fabrication of an autonomous self-healing biocoating with active antibacterial-agent-releasing capability, which can be applied not only in dentistry but also in other medical fields. | Kim, Ki-Hak; Mai, Hang-Nga; Hyun, Dong-Choon; Lee, Du-Hyeong | Kyungpook Natl Univ, Dept Polymer Sci & Engn, Daegu 41940, South Korea; Kyungpook Natl Univ, Inst Translat Res Dent, Daegu 41940, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Prosthodont, Daegu 41940, South Korea | ; Mai, Hang-Nga/Q-9865-2018 | 57301403400; 56964780900; 15834575400; 35770948000 | kdi1504@naver.com;maihangnga1403@knu.ac.kr;dong.hyun@knmac.kr;deweylee@knu.ac.kr;dong.hyun@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 5 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.07 | 2025-06-25 | 11 | 10 | coating; water-enabled self-healing; antibacterial-releasing; dental restorations; chlorhexidine; tannic acid | TANNIC-ACID; STREPTOCOCCUS-MUTANS; DENTISTRY; VERSATILE; ADHESION; POLYMER; FILMS | antibacterial-releasing; chlorhexi-dine; coating; dental restorations; tannic acid; water-enabled self-healing | antiinfective agent; chlorhexidine acetate; hydrogen; macrogol; poly(methyl methacrylate); tannin; water; animal cell; aqueous solution; Article; autonomous water enabled self healing coating; bacteriostatic activity; cell viability; coating (procedure); coating thickness; contact angle; dental restoration; drug coating; drug design; drug release; drug synthesis; emulsion; hydrogen bond; hydrophilicity; incubation time; mouse; nonhuman; precipitation; surface property | English | 2022 | 2022-05 | 10.3390/pharmaceutics14051005 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats | This study investigated the pharmacokinetics and tissue distribution of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor that is currently in phase three clinical trials. Enavogliflozin showed dose-proportional pharmacokinetics following intravenous and oral administration (doses of 0.3, 1, and 3 mg/kg) in both mice and rats. Oral bioavailability was 84.5-97.2% for mice and 56.3-62.1% for rats. Recovery of enavogliflozin as parent form from feces and urine was 39.3 +/- 3.5% and 6.6 +/- 0.7%, respectively, 72 h after its intravenous injection (1 mg/kg), suggesting higher biliary than urinary excretion in mice. Major biliary excretion was also suggested for rats, with 15.9 +/- 5.9% in fecal recovery and 0.7 +/- 0.2% in urinary recovery for 72 h, following intravenous injection (1 mg/kg). Enavogliflozin was highly distributed to the kidney, which was evidenced by the AUC ratio of kidney to plasma (i.e., 41.9 +/- 7.7 in mice following its oral administration of 1 mg/kg) and showed slow elimination from the kidney (i.e., T-1/2 of 29 h). It was also substantially distributed to the liver, stomach, and small and large intestine. In addition, the tissue distribution of enavogliflozin after single oral administration was not significantly altered by repeated oral administration for 7 days or 14 days. Overall, enavogliflozin displayed linear pharmacokinetics following intravenous and oral administration, significant kidney distribution, and favorable biliary excretion, but it was not accumulated in the plasma and major distributed tissues, following repeated oral administration for 2 weeks. These features may be beneficial for drug efficacy. However, species differences between rats and mice in metabolism and oral bioavailability should be considered as drug development continues. | Pang, Minyeong; Jeon, So Yeon; Choi, Min-Koo; Jeon, Ji-Hyeon; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook | Dankook Univ, Coll Pharm, Cheonan Si 31116, South Korea; Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Vessel Organ Interact Res Ctr VOICE,BK21 Four Com, Daegu 41566, South Korea; Daewoong Pharmaceut, Life Sci Inst, Yongin 17028, South Korea | 57488599500; 57226815842; 8695781400; 57204685946; 57215682552; 57215689019; 7201564500 | whatsupmy@naver.com;ojsw97@naver.com;minkoochoi@dankook.ac.kr;kei7016@naver.com;hy-chi138@daewoong.co.kr;jschoi172@daewoong.co.kr;isssong@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 6 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.39 | 2025-06-25 | 14 | 13 | sodium-glucose cotransporter 2 inhibitors; enavogliflozin; pharmacokinetics; kidney distribution | COTRANSPORTER 2 INHIBITORS; COMBINATION THERAPY; PLUS METFORMIN; ADD-ON; EMPAGLIFLOZIN; CANAGLIFLOZIN; 24-WEEK | enavogliflozin; kidney distribution; pharmacokinetics; sodium-glucose cotransporter 2 inhibitors | enavogliflozin; isoflurane; accuracy; animal model; area under the curve ratio; Article; biliary excretion; blood sampling; drug bioavailability; liquid chromatography-mass spectrometry; male; maximum plasma concentration; measurement precision; mouse; nonhuman; particle size; pharmacokinetics; quadrupole mass spectrometry; rat; time to maximum plasma concentration; tissue distribution; urinary excretion; volume of distribution | English | 2022 | 2022-06 | 10.3390/pharmaceutics14061210 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Potent and Selective Inhibition of CYP1A2 Enzyme by Obtusifolin and Its Chemopreventive Effects | Obtusifolin, a major anthraquinone component present in the seeds of Cassia tora, exhibits several biological activities, including the amelioration of memory impairment, prevention of breast cancer metastasis, and reduction of cartilage damage in osteoarthritis. We aimed to evaluate the inhibitory effects of obtusifolin and its analogs on CYP1A enzymes, which are responsible for activating procarcinogens, and investigate its inhibitory mechanism and chemopreventive effects. P450-selective substrates were incubated with human liver microsomes (HLMs) or recombinant CYP1A1 and CYP1A2 in the presence of obtusifolin and its four analogs. After incubation, the samples were analyzed using liquid chromatography-tandem mass spectrometry. Molecular docking simulations were performed using the crystal structure of CYP1A2 to identify the critical interactions between anthraquinones and human CYP1A2. Obtusifolin potently and selectively inhibited CYP1A2-mediated phenacetin O-deethylation (POD) with a K-i value of 0.031 mu M in a competitive inhibitory manner in HLMs, whereas it exhibited negligible inhibitory effect against other P450s (IC50 > 28.6 mu M). Obtusifolin also inhibited CYP1A1- and CYP1A2-mediated POD and ethoxyresorufin O-deethylation with IC50 values of <0.57 mu M when using recombinant enzymes. Our molecular docking models suggested that the high CYP1A2 inhibitory activity of obtusifolin may be attributed to the combination of hydrophobic interactions and hydrogen bonding. This is the first report of selective and potent inhibitory effects of obtusifolin against CYP1A, indicating their potential chemopreventive effects. | Park, Eun-Ji; Park, Keunwan; Durai, Prasannavenkatesh; Kim, Ki-Young; Park, So-Young; Kwon, Jaeyoung; Lee, Hee Ju; Pan, Cheol-Ho; Liu, Kwang-Hyeon | Kyungpook Natl Univ, Coll Pharm, Based Intelligent Novel Drug Discovery Educ Unit, BK21 FOUR KNU Community, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; KIST Gangneung Inst Nat Prod, Nat Prod Informat Res Ctr, Kangnung 25451, South Korea; Kyungpook Natl Univ, Mass Spectrometry Based Convergence Res Inst, Daegu 41566, South Korea | ; Durai, Prasannavenkatesh/AAU-4782-2021; Park, Keunwan/GLS-5403-2022; Kim, Kyung-Min Kim/C-7007-2014 | 57203611956; 16481120100; 55484636800; 58032476400; 57211630074; 56043667900; 12789973800; 7403224341; 55768214700 | panc@kist.re.kr;dstlkh@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 12 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.53 | 2025-06-25 | 3 | 5 | Cassiae semen; chemoprevention; inhibition; obtusifolin | POLYCYCLIC AROMATIC-HYDROCARBONS; CYTOCHROMES P450 1A1; ANTHRAQUINONES; SPECTROMETRY; VALIDATION; ACTIVATION; PLASMA; SEMEN; SEEDS; RHEIN | Cassiae semen; chemoprevention; CYP1A2; inhibition; obtusifolin | alpha naphthoflavone; amfebutamone; amodiaquine; anthraquinone derivative; chlorzoxazone; coumarin; cytochrome P450 1A1; cytochrome P450 1A2; cytochrome P450 2A6; cytochrome P450 2B6; cytochrome P450 2C19; cytochrome P450 2C8; cytochrome P450 2C9; cytochrome P450 2D6; cytochrome P450 2E1; cytochrome P450 3A; dextromethorphan; emodin; ethoxyresorufin; midazolam; obtusifolin; omeprazole; phenacetin; physcion; recombinant protein; rubrofusarin; tolbutamide; unclassified drug; Article; chemical modification; chemoprophylaxis; competitive inhibition; controlled study; crystal structure; enzyme activity; enzyme assay; ethoxyresorufin o deethylation; human; IC50; inhibition kinetics; liquid chromatography-mass spectrometry; liver microsome; molecular docking; phenacetin o deethylation; selective reaction monitoring; tandem mass spectrometry | English | 2022 | 2022-12 | 10.3390/pharmaceutics14122683 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Preclinical Evaluation of hnRNPA2B1 Antibody in Human Triple-Negative Breast Cancer MDA-MB-231 Cells via PET Imaging | Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Because TNBC lacks the expression of commonly targeted receptors, it is challenging to develop a new imaging agent for this cancer subtype. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are RNA-protein complexes that have been linked to tumor development and progression. Considering the high expression of hnRNPA2B1, an hnRNP subtype, in TNBC MDA-MB-231 cells, this study aimed to develop a novel hnRNPA2B1 antibody-based nuclear imaging agent. The hnRNPA2B1-specific antibody was radiolabeled with Cu-64 and evaluated in vitro and in vivo. The trans-cyclooctene (TCO) was functionalized on the antibody to obtain hnRNP-PEG(4)-TCO and reactive tetrazine (Tz) on the ultrastable bifunctional chelator PCB-TE2A-alkyne to yield PCB-TE2A-Tz for the inverse electron demand Diels-Alder reaction. The Cu-64-radiolabeled antibody was administered and imaged at 1-18 h time points for conventional imaging. Alternatively, the unlabeled antibody conjugate was administered, and 48 h later radiolabeled Cu-64-PCB-TE2A-Tz was administered to the same mice for the pretargeting strategy and imaged at the same time intervals for direct comparison. The tumor was successfully visualized in both strategies, and comparatively, pretargeting showed superior results. The Cu-64-PCB-TE2A-Tz was successfully clicked at the tumor site with hnRNP-PEG(4)-TCO and the non-clicked were concurrently eliminated. This led to increase the tumor uptake with extremely high tumor-to-background ratio manifested by positron emission tomography (PET) imaging and biodistribution studies. | Bhise, Abhinav; Park, Hyun; Lee, Woonghee; Sarkar, Swarbhanu; Ha, Yeong Su; Rajkumar, Subramani; Nam, Bora; Lim, Jeong Eun; Huynh, Phuong Tu; Lee, Kiwoong; Son, Ji-Yoon; Kim, Jung Young; Lee, Kyo Chul; Yoo, Jeongsoo | Kyungpook Natl Univ, Sch Med, Plus KNU Biomed Convergence Program BK21, Dept Mol Med, Daegu, South Korea; Korea Inst Radiol & Med Sci, Div Appl RI, Seoul 01812, South Korea | ; Kim, Kyunghoon/AGO-0079-2022; Bhise, Abhinav/MVY-6473-2025; Sarkar, Swarbhanu/ISS-1138-2023 | 57210174595; 56175671100; 55881469700; 36603493100; 36720940600; 57224804062; 57222734356; 57732661800; 56829091800; 57222365137; 57211247483; 7601371677; 42661704100; 8215136400 | yooj@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 8 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.32 | 2025-06-25 | 3 | 3 | immuno-PET; pretargeting; triple-negative breast cancer; nuclear imaging | IMMUNO-PET; CONJUGATION; COMPLEXES; STRATEGY | hnRNPA2B1; immuno-PET; nuclear imaging; pretargeting; triple-negative breast cancer | English | 2022 | 2022-08 | 10.3390/pharmaceutics14081677 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Preventive and Therapeutic Effects of Krill Oil on Obesity and Obesity-Induced Metabolic Syndromes in High-Fat Diet-Fed Mice | Obesity increases the risks of metabolic syndromes including nonalcoholic fatty liver disease (NAFLD), diabetic dyslipidemia, and chronic kidney disease. Dietary krill oil (KO) has shown antioxidant and anti-inflammatory properties, thereby being a therapeutic potential for obesity-induced metabolic syndromes. Thus, the effects of KO on lipid metabolic alteration were examined in a high-fat diet (HFD)-fed mice model. The HFD model (n = 10 per group) received an oral gavage with distilled water as a control, metformin at 250 mg/kg, and KO at 400, 200, and 100 mg/kg for 12 weeks. The HFD-induced weight gain and fat deposition were significantly reduced in the KO treatments compared with the control. Blood levels were lower in parameters for NAFLD (e.g., alanine aminotransferase, and triglyceride), type 2 diabetes (e.g., glucose and insulin), and renal dysfunction (e.g., blood urea nitrogen and creatinine) by the KO treatments. The KO inhibited lipid synthesis through the modification of gene expressions in the liver and adipose tissues and adipokine-mediated pathways. Furthermore, KO showed hepatic antioxidant activities and glucose lowering effects. Histopathological analyses revealed that the KO ameliorated the hepatic steatosis, pancreatic endocrine/exocrine alteration, adipose tissue hypertrophy, and renal steatosis. These analyses suggest that KO may be promising for inhibiting obesity and metabolic syndromes. | Hwang, Seung-Min; Kim, Yeong Uk; Kim, Jong-Kyu; Chun, Yoon-Seok; Kwon, Young-Sam; Ku, Sae-Kwang; Song, Chang-Hyun | Kyungpook Natl Univ, Coll Vet Med, Dept Vet Surg, Daegu 41566, South Korea; Yeungnam Univ, Coll Med, Dept Urol, Daegu 42415, South Korea; AriBnC Co Ltd, Yongin 16914, South Korea; Daegu Haany Univ, Coll Korean Med, Dept Anat & Histol, Gyongsan 38610, South Korea | Kim, Young-Il/ISS-7678-2023 | 57855271100; 56678184600; 37090794500; 57209803368; 7403459426; 7006331005; 24403187800 | vet1st@knu.ac.kr;jojo9174@hanmail.net;swrhrnak@gmail.com;ceochun@aribnc.com;kwon@knu.ac.kr;gucci200@dhu.ac.kr;dvmsong@dhu.ac.kr; | MARINE DRUGS | MAR DRUGS | 1660-3397 | 20 | 8 | SCIE | CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 2.18 | 2025-06-25 | 19 | 17 | obesity; diabetes; NAFLD; T2D; dyslipidemia; HFD; steatosis; metformin; marine; PUFA | ADIPOSE-TISSUE; FISH-OIL; EUPHAUSIA-SUPERBA; LIVER-DISEASE; ACIDS; SUPPLEMENTATION; METFORMIN; HEALTH; DYSLIPIDEMIA; INFLAMMATION | diabetes; dyslipidemia; HFD; marine; metformin; NAFLD; obesity; PUFA; steatosis; T2D | Animals; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Euphausiacea; Glucose; Insulin Resistance; Liver; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Triglycerides; antioxidant; glucose; triacylglycerol; adverse event; animal; C57BL mouse; complication; insulin resistance; krill; lipid diet; liver; metabolic syndrome X; metabolism; mouse; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; obesity | English | 2022 | 2022-08 | 10.3390/md20080483 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Regulation of Inflammation-Mediated Endothelial to Mesenchymal Transition with Echinochrome a for Improving Myocardial Dysfunction | Endothelial-mesenchymal transition (EndMT) is a process by which endothelial cells (ECs) transition into mesenchymal cells (e.g., myofibroblasts and smooth muscle cells) and induce fibrosis of cells/tissues, due to ischemic conditions in the heart. Previously, we reported that echinochrome A (EchA) derived from sea urchin shells can modulate cardiovascular disease by promoting anti-inflammatory and antioxidant activity; however, the mechanism underlying these effects was unclear. We investigated the role of EchA in the EndMT process by treating human umbilical vein ECs (HUVECs) with TGF-beta 2 and IL-1 beta, and confirmed the regulation of cell migration, inflammatory, oxidative responses and mitochondrial dysfunction. Moreover, we developed an EndMT-induced myocardial infarction (MI) model to investigate the effect of EchA in vivo. After EchA was administered once a day for a total of 3 days, the histological and functional improvement of the myocardium was investigated to confirm the control of the EndMT. We concluded that EchA negatively regulates early or inflammation-related EndMT and reduces the myofibroblast proportion and fibrosis area, meaning that it may be a potential therapy for cardiac regeneration or cardioprotection from scar formation and cardiac fibrosis due to tissue granulation. Our findings encourage the study of marine bioactive compounds for the discovery of new therapeutics for recovering ischemic cardiac injuries. | Song, Byeong-Wook; Kim, Sejin; Kim, Ran; Jeong, Seongtae; Moon, Hanbyeol; Kim, Hojin; Vasileva, Elena A. A.; Mishchenko, Natalia P. P.; Fedoreyev, Sergey A. A.; Stonik, Valentin A. A.; Lee, Min Young; Kim, Jongmin; Kim, Hyoung Kyu; Han, Jin; Chang, Woochul | Catholic Kwandong Univ, Int St Marys Hosp, Inst Biomed Convergence, Incheon 22711, South Korea; Pusan Natl Univ, Coll Educ, Dept Biol Educ, Busan 46241, South Korea; Russian Acad Sci, GB Elyakov Pacific Inst Bioorgan Chem, Far Eastern Branch, Vladivostok 690022, Russia; Kyungpook Natl Univ, Coll Pharm, Dept Mol Physiol, Daegu 41566, South Korea; Sookmyung Womens Univ, Dept Life Syst, Seoul 04310, South Korea; Inje Univ, Coll Med, Cardiovasc & Metab Dis Ctr, Smart Marine Therapeut Ctr, Busan 47392, South Korea | ; Song, Byeong-Wook/R-1077-2019; Stonik, Valentin/O-1985-2013; Kim, Hyung/J-5451-2012; Mishchenko, Natalia/M-8898-2013; Kim, Jong-Min/J-5435-2012; Vasileva, Elena/B-8155-2018; Fedoreyev, Sergey/M-8861-2013 | 24345452200; 57896283200; 55859511600; 57258106400; 57201312637; 57896283300; 56375223800; 7004534945; 6602512295; 57192933413; 15119890400; 37112415400; 57189208930; 34770178300; 12797539700 | phyhanj@inje.ac.kr;wchang1975@pusan.ac.kr; | MARINE DRUGS | MAR DRUGS | 1660-3397 | 20 | 12 | SCIE | CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.92 | 2025-06-25 | 13 | 16 | endothelial-mesenchymal transition; echinochrome A; myocardial infarction; cardiac fibrosis | CELLS; CONTRIBUTES; ACTIVATION; FIBROSIS; PROGRESSION | cardiac fibrosis; echinochrome A; endothelial–mesenchymal transition; myocardial infarction | Cells, Cultured; Epithelial-Mesenchymal Transition; Fibrosis; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Signal Transduction; antiinflammatory agent; echinochrome A; interleukin 1beta; Rho guanine nucleotide binding protein; transforming growth factor beta2; unclassified drug; echinochrome A; antiinflammatory activity; antioxidant activity; Article; cardiac muscle; cell migration; controlled study; disorders of mitochondrial functions; endothelium cell; epithelial mesenchymal transition; heart infarction; heart muscle fibrosis; heart muscle ischemia; heart protection; histopathology; human; human cell; in vivo study; inflammation; liquid chromatography; mass spectrometry; mitochondrial membrane potential; myocardial disease; myofibroblast; scar formation; smooth muscle cell; umbilical vein endothelial cell; cell culture; fibrosis; inflammation; pathology; signal transduction | English | 2022 | 2022-12 | 10.3390/md20120756 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Role of Nrf2, STAT3, and Src as Molecular Targets for Cancer Chemoprevention | Cancer is a complex and multistage disease that affects various intracellular pathways, leading to rapid cell proliferation, angiogenesis, cell motility, and migration, supported by antiapoptotic mechanisms. Chemoprevention is a new strategy to counteract cancer; to either prevent its incidence or suppress its progression. In this strategy, chemopreventive agents target molecules involved in multiple pathways of cancer initiation and progression. Nrf2, STAT3, and Src are promising molecular candidates that could be targeted for chemoprevention. Nrf2 is involved in the expression of antioxidant and phase II metabolizing enzymes, which have direct antiproliferative action as well as indirect activities of reducing oxidative stress and eliminating carcinogens. Similarly, its cross-talk with NF-kappa B has great anti-inflammatory potential, which can be utilized in inflammation-induced/associated cancers. STAT3, on the other hand, is involved in multiple pathways of cancer initiation and progression. Activation, phosphorylation, dimerization, and nuclear translocation are associated with tumor cell proliferation and angiogenesis. Src, being the first oncogene to be discovered, is important due to its convergence with many upstream stimuli, its cross-talk with other potential molecular targets, such as STAT3, and its ability to modify the cell cytoskeleton, making it important in cancer invasion and metastasis. Therefore, the development of natural/synthetic molecules and/or design of a regimen that can reduce oxidative stress and inflammation in the tumor microenvironment and stop multiple cellular targets in cancer to stop its initiation or retard its progression can form newer chemopreventive agents. | Ahsan, Haseeb; Ul Islam, Salman; Ahmed, Muhammad Bilal; Lee, Young Sup | Univ Peshawar, Fac Life & Environm Sci, Dept Pharm, Peshawar 25120, Pakistan; CECOS Univ, Dept Pharm, Peshawar 25000, Pakistan; Kyungpook Natl Univ, Sch Life Sci, BK21 FOUR KNU Creat BioRes Grp, Daegu 41566, South Korea | Ahsan, Haseeb/Y-2866-2018; Ahmed, Muhammad/ABA-8180-2021 | 57531232400; 56985186700; 58689879600; 36013628200 | yselee@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 9 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.39 | 2025-06-25 | 11 | 12 | Nrf2; STAT3; Src; NF kappa B; chemoprevention; inflammation | NF-KAPPA-B; SIGNAL TRANSDUCER; INCREASED SUSCEPTIBILITY; TERT-BUTYLHYDROQUINONE; OXIDATIVE STRESS; VEGF EXPRESSION; CELL INVASION; COLITIS; PATHWAY; INFLAMMATION | chemoprevention; inflammation; NF κB; Nrf2; Src; STAT3 | antineoplastic agent; protein kinase p60; STAT3 protein; transcription factor Nrf2; cancer prevention; chemosensitivity; colitis-associated cancer; drug targeting; human; inflammation; malignant neoplasm; molecularly targeted therapy; nonhuman; Nrf2 signaling; protein expression; protein function; Review | English | 2022 | 2022-09 | 10.3390/pharmaceutics14091775 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Toxicokinetics of β-Amanitin in Mice and In Vitro Drug-Drug Interaction Potential | The toxicokinetics of beta-amanitin, a toxic bicyclic octapeptide present abundantly in Amanitaceae mushrooms, was evaluated in mice after intravenous (iv) and oral administration. The area under plasma concentration curves (AUC) following iv injection increased in proportion to doses of 0.2, 0.4, and 0.8 mg/kg. beta-amanitin disappeared rapidly from plasma with a half-life of 18.3-33.6 min, and 52.3% of the iv dose was recovered as a parent form. After oral administration, the AUC again increased in proportion with doses of 2, 5, and 10 mg/kg. Absolute bioavailability was 7.3-9.4%, which resulted in 72.4% of fecal recovery from orally administered beta-amanitin. Tissue-to-plasma AUC ratios of orally administered beta-amanitin were the highest in the intestine and stomach. It also readily distributed to kidney > spleen > lung > liver approximate to heart. Distribution to intestines, kidneys, and the liver is in agreement with previously reported target organs after acute amatoxin poisoning. In addition, beta-amanitin weakly or negligibly inhibited major cytochrome P450 and 5 '-diphospho-glucuronosyltransferase activities in human liver microsomes and suppressed drug transport functions in mammalian cells that overexpress transporters, suggesting the remote drug interaction potentials caused by beta-amanitin exposure. | Bang, Young Yoon; Song, Im-Sook; Lee, Min Seo; Lim, Chang Ho; Cho, Yong-Yeon; Lee, Joo Young; Kang, Han Chang; Lee, Hye Suk | Catholic Univ Korea, Coll Pharm, Bucheon 14662, South Korea; Catholic Univ Korea, BK21 Four Sponsored Adv Program Smart, Bucheon 14662, South Korea; Kyungpook Natl Univ, Coll Pharm & Res Inst Pharmaceut Sci, BK21 FOUR Community Based Intelligent Novel Drug, Vessel Organ Interact Res Ctr VOICE, Daegu 41566, South Korea | ; Cho, Yong-Yeon/AAD-4263-2020; Kang, Han/I-5999-2019 | 57317443000; 7201564500; 57225079010; 57317155800; 55472207900; 57215684977; 36150873700; 35316111800 | js7123258@catholic.ac.kr;isssong@knu.ac.kr;minseo.lee@catholic.ac.kr;maxlim8580@catholic.ac.kr;yongyeon@catholic.ac.kr;joolee@catholic.ac.kr;hckang@catholic.ac.kr;sianalee@catholic.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 4 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.39 | 2025-06-25 | 13 | 13 | beta-amanitin; mouse; toxicokinetics; tissue distribution; drug interaction; drug-metabolizing enzymes; drug transporters | ALPHA-AMANITIN; TOXICITY; QUANTIFICATION; PHALLOIDES; AMATOXINS; IDENTIFICATION; TRANSPORTERS; TOXINS | drug interaction; drug transporters; drug-metabolizing enzymes; mouse; tissue distribution; toxicokinetics; β-amanitin | beta amanitin; drug metabolizing enzyme; glucuronosyltransferase; octapeptide; animal experiment; animal tissue; area under the curve; article; Article; drug transport; feces; gene overexpression; half life time; heart; in vitro study; intestine; kidney; liver microsome; lung; male; mammal cell; mouse; mushroom; nonhuman; oral drug administration; spleen; stomach; target organ; tissue distribution; toxicokinetics | English | 2022 | 2022-04 | 10.3390/pharmaceutics14040774 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Electrochemical performance of asymmetric device using the nickel-zinc organometallic structure | Bimetallic metal-organic frameworks (BMOFs) have developed as novel candidates for electrodes due to their high-performance energy storage applications. We attempted to develop a new three-dimensional (3D) ordered structure of nickel-zinc MOFs (NZMOF), grown in situ on carbon cloth (NZMOF/CC) using a solvo-hydrothermal strategy to increase the stored energy. A notable capacitance of 456.8 F/g was achieved for this electrode at 1 A/g. In addition, the NZMOF/CC//AC/CC assembled split-cell asymmetric supercapacitor device (SASD) achieved an excellent energy and power densities of 38.54 Wh/kg and 750 W/kg, respectively, with a capacity retention of 87.27% after 5000 cycles, which is better than that of conventional supercapacitors. Additionally, this study is easy and controllable, providing a viable approach for fabricating hybrid electrode materials for high-performance energy storage systems. | Zeng, Jie; Devarayapalli, Kamakshaiah Charyulu; Li, Changping; Vattikuti, S. V. Prabhakar; Shim, Jaesool | Yeungnam Univ, Sch Mech Engn, Gyongsan 38541, South Korea; Kyungpook Natl Univ, Dept Environm Engn, Daegu, South Korea; Hunan Univ Sci & Technol, Coll Mech & Elect Engn, Xiangtan 411201, Peoples R China | ; VATTIKUTI, S/I-5237-2019 | 57349068900; 15069351300; 36518956600; 57542619100; 16040548500 | 15073200235@163.com;vsvprabu@gmail.com;jshim@ynu.ac.kr; | APPLIED ORGANOMETALLIC CHEMISTRY | APPL ORGANOMET CHEM | 0268-2605 | 1099-0739 | 36 | 6 | SCIE | CHEMISTRY, APPLIED;CHEMISTRY, INORGANIC & NUCLEAR | 2022 | 3.9 | 17.9 | 0.33 | 2025-06-25 | 4 | 4 | asymmetric device; bimetallic MOFs; electrode materials; energy storage; supercapacitor | METAL-ORGANIC-FRAMEWORK; 3D NANOFLAKE ARRAY; ENHANCED PERFORMANCE; THIN SHEETS; ELECTRODES; DESIGN; FABRICATION; MORPHOLOGY; REPLICAS | asymmetric device; bimetallic MOFs; electrode materials; energy storage; supercapacitor | Electrochemical electrodes; Energy storage; Hybrid materials; Nickel; Organometallics; Storage (materials); Zinc; Asymmetric device; Bimetallic MOF; Bimetallics; Electrochemical performance; Electrode material; Energy storage applications; Metalorganic frameworks (MOFs); Ordered structures; Organometallic structure; Performance; Supercapacitor | English | 2022 | 2022-06 | 10.1002/aoc.6699 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Sphingosine kinase-dependent regulation of pro-resolving lipid mediators in Alzheimer's disease | The majority of peripheral and central nervous system disorders are related to hyperactive inflammatory responses, leading to irreversible and persistent cellular defects, functional impairments, and behavioral deficits. Advances in our understanding of these disorders have revealed the disruption of inflammation resolution pathways due to abrogated responses by specialized pro-resolving lipid mediators (SPMs). SPMs comprise a class of bioactive lipids and cell signaling molecules that function to resolve inflammation, pain, and function in host defense and tissue remodeling. Their cellular and systemic levels during physiology and pathology are regulated by sphingosine kinases (especially SphK1) that act by monitoring cyclooxygenase-2 (COX2), a potent inhibitor of SPMs production. This review presents the current understanding of the convergent mechanisms shared by bioactive lipids with SphK1 and COX2 in the etiology of chronic inflammatory disorders, focusing on neuroinflammation, as well as describes the translational directions of this trilogy for the treatment of Alzheimer's disease. | Ayub, Maria; Jin, Hee Kyung; Bae, Jae-sung | Kyungpook Natl Univ, KNU Alzheimers Dis Res Inst, Daegu 41566, South Korea; Kyungpook Natl Univ, Sch Med, Dept Physiol, Daegu 41944, South Korea; Kyungpook Natl Univ, Coll Vet Med, Dept Lab Anim Med, Daegu 41566, South Korea | Kim, Young/T-8521-2019; Bae, Jae-sung/AAM-8663-2021; Ayub, Maria/HBK-8730-2022 | 57223388486; 8088145800; 35209510400 | jsbae@knu.ac.kr; | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | BBA-MOL CELL BIOL L | 1388-1981 | 1879-2618 | 1867 | 5 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS;CELL BIOLOGY | 2022 | 4.8 | 17.9 | 0.34 | 2025-06-25 | 4 | 4 | Sphingosine kinase 1; COX2; Lipid mediators; Inflammation; Alzheimer's disease | NITRIC-OXIDE SYNTHASE; ALPHA-SYNUCLEIN; FATTY-ACIDS; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; INFLAMMATION; CYCLOOXYGENASE-2; RESOLUTION; INHIBITION; EXPRESSION | Alzheimer's disease; COX2; Inflammation; Lipid mediators; Sphingosine kinase 1 | Alzheimer Disease; Cyclooxygenase 2; Eicosanoids; Humans; Inflammation; Phosphotransferases (Alcohol Group Acceptor); acetylsalicylic acid; alpha synuclein; C reactive protein; caspase; ceramide; cyclooxygenase 2; cyclooxygenase 2 inhibitor; cytokine; gamma secretase; icosanoid; interleukin 1beta; interleukin 6; lipid; lipoxin; nitric oxide; polyketide; polyunsaturated fatty acid; reactive oxygen metabolite; sphingosine 1 phosphate; sphingosine kinase; tumor necrosis factor; cyclooxygenase 2; icosanoid; phosphotransferase; sphingosine kinase; Alzheimer disease; angiogenesis; apoptosis; Article; autoimmune disease; cardiovascular disease; CD8+ T lymphocyte; cell aging; degenerative disease; demyelination; efferocytosis; environmental factor; epilepsy; fibrosis; functional disease; gene expression; hippocampus; human; immunocompetent cell; inflammatory bowel disease; ischemic stroke; liver fibrosis; mental disease; metabolic disorder; multiple sclerosis; nervous system inflammation; nonhuman; oligodendroglia; pain; Parkinson disease; randomized controlled trial (topic); regulatory mechanism; spinal cord injury; synaptic transmission; traumatic brain injury; virus infection; inflammation; metabolism | English | 2022 | 2022-05 | 10.1016/j.bbalip.2022.159126 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Synthesis of benzo[4,5]imidazo[1,2-a]indolo[1,2-c]quinazolines from 2-(2-bromoaryl)indoles and 2-methoxybenzimidazoles under recyclable magnetic MOF-199 catalysis | 2-(2-Bromoaryl)indoles react with 2-methoxybenzimidazoles in DMF in the presence of a catalytic amount of recyclable Fe3O4@SiO2@MOF-199 along with K2CO3 to afford a series of benzo[4,5]imidazo[1,2-a]indolo[1,2-c]quinazolines in good yields. The reaction applies to a broad scope of 2-(2-bromoaryl)indoles containing electron-donating or -withdrawing substituents on bromophenyl and indole moieties, and alkyl substituents at 3-position of indole moiety. A reaction pathway involving a copper-catalyzed Ullmann-type C (sp(2))-N coupling and an addition-elimination nucleophilic aromatic substitution via Meisenheimer complex followed by cyclocondensation is proposed for this catalytic process. The Fe3O4@SiO2@MOF-199 catalyst could be recovered and reused several times without any change of catalytic activity. | Kim, Min Jeong; Lee, Seong Weon; Pham Duy Quang Dao; Cho, Chan Sik | Kyungpook Natl Univ, Dept Appl Chem, 80 Daehakro, Daegu 41566, South Korea | ; Dao, P. D. Quang/AAR-9880-2021 | 57215818497; 57737643600; 57194217171; 7403100019 | cscho@knu.ac.kr; | APPLIED ORGANOMETALLIC CHEMISTRY | APPL ORGANOMET CHEM | 0268-2605 | 1099-0739 | 36 | 11 | SCIE | CHEMISTRY, APPLIED;CHEMISTRY, INORGANIC & NUCLEAR | 2022 | 3.9 | 17.9 | 0.33 | 2025-06-25 | 4 | 4 | 2-methoxybenzimidazole; C-N coupling; cyclization; N-fused heterocycles; recyclable copper catalyst | FUSED BENZIMIDAZOLE-4,7-DIONES; GREEN SYNTHESIS; EXTRACT; HYDRODEHALOGENATION; NANOCOMPOSITE; REDUCTION; CR(VI); LIGNIN | 2-methoxybenzimidazole; C-N coupling; cyclization; N-fused heterocycles; recyclable copper catalyst | Catalysis; Catalyst activity; Copper; Magnetite; Polycyclic aromatic hydrocarbons; Potash; Silica; Silicon; 2-methoxybenzimidazole; C-N coupling; Catalytic amounts; Cyclizations; Heterocycles; Indole moiety; N-fused heterocycle; Quinazolines; Recyclable copper catalyst; Recyclables; Cyclization | English | 2022 | 2022-11 | 10.1002/aoc.6871 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | A Transparent Self-Healing Polyurethane-Isophorone-Diisocyanate Elastomer Based on Hydrogen-Bonding Interactions | Self-healing elastomers that can repair physical damage and extend their service life in medium- and low-temperature environments have attracted considerable attention in the field of flexible materials. However, the self-healing polyurethane (PU) healing process reported in previous studies regularly needs to be supported by high heating temperature and long healing time. In this study, a simple method was developed to synthesize a self-healing PU film using isophorone diisocyanate (IPDI) and a transparent rubber solution. The high transmittance (89%) of the resulting polyurethane-isophorone-diisocyanate (PUI) film was confirmed by UV-vis spectroscopy. FT-IR spectroscopy revealed that the hydrogen bonds formed by the imino group and the C=O bonds in IPDI and the transparent rubber facilitated the self-healing of the PUI composite film. The optical microscope observed that the self-healing PU can complete the self-healing of cracks in a short period. Moreover, a PUI film restored at 60 degrees C for 1 h withstood a load of 1 kg. Tensile tests showed that healing efficiencies of 82% and 99% were achieved by the PUI film healed at 60 degrees C for 1 and 2 h, respectively. A self-healing experiment conducted on a silver-nanowire/PUI-film system confirmed the synergistic recovery performance of PUI on a conductive coating. The self-healing PUI elastomers might have potential commercial prospects in transparent coatings, self-healing antibacterial films, robotic skins, and flexible electronics. | Ma, Junfei; Lee, Ga-Hyun; Kim, Ji-Hyeon; Kim, Sang-Woo; Jo, Sungjin; Kim, Chang Su | Korea Inst Mat Sci KIMS, Dept Nanobio Convergence, Chang Won 51508, South Korea; Kyungpook Natl Univ, Sch Architectural Civil Environm & Energy Engn, Daegu 41566, South Korea; Korea Inst Mat Sci KIMS, Dept Carbon Composites Res Div, Chang Won 51508, South Korea | 57207769424; 57215123354; 57210338058; 59457006800; 7101724027; 57201346735 | ready@kims.re.kr;sungjin@knu.ac.kr;cskim1025@kims.re.kr; | ACS APPLIED POLYMER MATERIALS | ACS APPL POLYM MATER | 2637-6105 | 4 | 4 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY;POLYMER SCIENCE | 2022 | 5 | 18.0 | 3.16 | 2025-06-25 | 35 | 36 | self-healing elastomer; polyurethane; high transmittance; isophorone diisocyanate; hydrogen bonds | ELECTRICAL-CONDUCTIVITY; POLYMER NETWORK; MICROCAPSULES; SCAFFOLDS; STRENGTH; ABILITY; DESIGN | high transmittance; hydrogen bonds; isophorone diisocyanate; polyurethane; self-healing elastomer | Coatings; Composite films; Flexible electronics; Plastics; Polyurethanes; Rubber; Self-healing materials; Temperature; Tensile testing; Ultraviolet visible spectroscopy; Flexible materials; Healing process; High transmittance; Hydrogen bonding interactions; Isophorone diisocyanate; Low temperature environment; Medium temperature; Physical damages; Self-healing; Self-healing elastomer; Hydrogen bonds | English | 2022 | 2022-04-08 | 10.1021/acsapm.1c01799 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: